AstraZeneca's PARP inhibitor gains market edge with breast cancer approval
- The Food and Drug Administration on Friday cleared AstraZeneca plc's Lynparza to treat a segment of the breast cancer population, a noteworthy first for an emerging class of therapies known as PARP inhibitors, which have thus far gained approval just in ovarian cancer.
- Lynparza is now OK'd for metastatic breast cancer patients who have an inherited mutation in their BRCA genes. Those genes normally function as tumor suppressors.
- More specifically, the FDA approved the drug for patients with HER2-negative metastatic breast cancer who had already received chemotherapy. It may also be applicable to patients with HR-positive breast cancer, but only if they can't take or don't respond to endocrine therapy, according to a Jan. 12 statement.
AstraZeneca still enjoys the perks of being first to market with its PARP inhibitor. Lynparza (olaparib) sales were $81 million from July to September, whereas net revenues were $16.8 million and $39.4 million for Clovis Oncology Inc.'s Rubraca (rucaparib) and Tesaro Inc.'s Zejula (niraparib), respectively.
Yet Lynparza's place at the top of the PARP pile hasn't been unshakable. While overall sales of the drug increased 40% year-over-year during the third quarter, they were down 9% in the U.S. due to competitor products. Tesaro, for one, touted how Zejula snagged a 60% market share of the ovarian cancer population treated with a PARP inhibitor. The Massachusetts biotech, along with Clovis, are also working to expand the labels for their drugs.
They'll have to work harder, though. The FDA's new approval hands Lynparza its third indication while Zejula and Rubraca each hold one. It also opens the door to a whole new patient population. Research published in the Journal of Clinical Oncology determined patients with inherited BRCA mutations have a 50% to 70% risk of developing breast cancer.
On a larger scale, the approval helps justify why AstraZeneca is betting so heavily on Lynparza.
Following the devastating failure of its PD-L1 inhibitor Imfinzi (durvalumab) in the MYSTIC trial, AstraZeneca inked an $8.5 billion deal with Merck & Co. to, in part, investigate the combination of Lynparza and Keytruda (pembrolizumab).
"This additional approval for Lynparza represents an important advance for women with HER2-negative metastatic breast cancer with a germline BRCA mutation, which is a difficult-to-treat cancer. Moreover, this approval adds further impetus to our important collaboration with AstraZeneca in developing cancer therapies," said Roy Baynes, chief medical officer at Merck Research Laboratories, said in the Jan. 12 statement.
The FDA made its decision based on positive results from the Phase 3 trial, which showed about 60% of patients treated with Lynparza experienced tumor shrinkage. OlympiAD enrolled 302 patients with HER2-negative, BRCA-mutated metastatic breast cancer.
"This approval demonstrates the current paradigm of developing drugs that target the underlying genetic causes of a cancer, often across cancer types," Richard Pazdur, acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, said in a statement from the agency.
AstraZeneca shares were up less than 1% to $35.69 apiece in Friday afternoon trading.
Follow Jacob Bell on Twitter